Shanghai Shyndec Pharmaceutical's subsidiary has obtained the drug registration certificate for sustained-release quetiapine fumarate tablets.
Guoyao Xian Dai (600420.SH) announced recently that its wholly-owned subsidiary, Guoyao Group Industrial Co., Ltd. (referred to as Guoyao Industrial), has received the drug registration certificate for Quetiapine Fumarate Extended-Release Tablets approved and issued by the National Medical Products Administration.
Shanghai Shyndec Pharmaceutical (600420.SH) announced that its wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd. (referred to as CNPG Industrial), recently received the approved and issued Drug Registration Certificate for Quetiapine Sustained-Release Tablets by the National Medical Products Administration.
Quetiapine Sustained-Release Tablets is an atypical antipsychotic medication that regulates brain nerve activity. It is primarily used to control schizophrenia and bipolar disorder, stabilizing mood, reducing hallucinations, and improving cognitive function. It helps patients recover normal cognitive and social functions.
Related Articles
The IPO of Da Pu Micro Entrepreneurs Board is approved, and the cumulative shipment volume of enterprise-level SSDs has reached over 4900PB.
East Test and Control Technology Innovation Board IPO has been accepted and plans to raise 1.1 billion yuan.
CSRC approves the resubmission of materials for the Sci-Tech Innovation Board IPO registration.
The IPO of Da Pu Micro Entrepreneurs Board is approved, and the cumulative shipment volume of enterprise-level SSDs has reached over 4900PB.
East Test and Control Technology Innovation Board IPO has been accepted and plans to raise 1.1 billion yuan.
CSRC approves the resubmission of materials for the Sci-Tech Innovation Board IPO registration.
RECOMMEND
